title: The drug-based pipeline against restenosis.
abstract: More than 1 million percutaneous coronary interventions (PCIs) are performed yearly worldwide. Restenosis is the recurrent narrowing that can occur within 6 months following an initially successful PCI. Although drug-eluting stents have accomplished remarkable success, restenosis has not been eliminated and optimisation of both the polymers and drugs associated with them is desirable. This article reviews the presently available and potential preventive approaches against restenosis, including the sirolimus and paclitaxel drug-eluting stents.
authors.affiliation: Montreal Heart Institute, Department of Medicine, 5000 Belanger Street, Montreal, Canada.
authors.forename: Pierre-Frédéric
authors.initials: PF
authors.lastname: Keller
authors.forename: Reda
authors.initials: R
authors.lastname: Ibrahim
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Tardif
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000737:chemistry; D023903:Coronary Restenosis / Q000188:drug therapy* / Q000473:pathology*; D016503:Drug Delivery Systems / Q000379:methods*; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans
chemical_list: D000893:Anti-Inflammatory Agents; D015507:Drugs, Investigational